Cargando…

Advances in RIPK1 kinase inhibitors

Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lu, Zhang, Xiaoqin, Ou, Yaqing, Liu, Maoyu, Yu, Dongke, Song, Zhiheng, Niu, Lihong, Zhang, Lijuan, Shi, Jianyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554302/
https://www.ncbi.nlm.nih.gov/pubmed/36249746
http://dx.doi.org/10.3389/fphar.2022.976435
_version_ 1784806663111311360
author Chen, Lu
Zhang, Xiaoqin
Ou, Yaqing
Liu, Maoyu
Yu, Dongke
Song, Zhiheng
Niu, Lihong
Zhang, Lijuan
Shi, Jianyou
author_facet Chen, Lu
Zhang, Xiaoqin
Ou, Yaqing
Liu, Maoyu
Yu, Dongke
Song, Zhiheng
Niu, Lihong
Zhang, Lijuan
Shi, Jianyou
author_sort Chen, Lu
collection PubMed
description Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Alzheimer’s disease, and malignancy. At present, the reported inhibitors are divided into four categories. The first category is the type I ATP-competitive kinase inhibitors that targets the area occupied by the ATP adenylate ring; The second category is type Ⅱ ATP competitive kinase inhibitors targeting the DLG-out conformation of RIPK1; The third category is type Ⅲ kinase inhibitors that compete for binding to allosteric sites near ATP pockets; The last category is others. This paper reviews the structure, biological function, and recent research progress of receptor interaction protein-1 kinase inhibitors.
format Online
Article
Text
id pubmed-9554302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95543022022-10-13 Advances in RIPK1 kinase inhibitors Chen, Lu Zhang, Xiaoqin Ou, Yaqing Liu, Maoyu Yu, Dongke Song, Zhiheng Niu, Lihong Zhang, Lijuan Shi, Jianyou Front Pharmacol Pharmacology Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Alzheimer’s disease, and malignancy. At present, the reported inhibitors are divided into four categories. The first category is the type I ATP-competitive kinase inhibitors that targets the area occupied by the ATP adenylate ring; The second category is type Ⅱ ATP competitive kinase inhibitors targeting the DLG-out conformation of RIPK1; The third category is type Ⅲ kinase inhibitors that compete for binding to allosteric sites near ATP pockets; The last category is others. This paper reviews the structure, biological function, and recent research progress of receptor interaction protein-1 kinase inhibitors. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9554302/ /pubmed/36249746 http://dx.doi.org/10.3389/fphar.2022.976435 Text en Copyright © 2022 Chen, Zhang, Ou, Liu, Yu, Song, Niu, Zhang and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Lu
Zhang, Xiaoqin
Ou, Yaqing
Liu, Maoyu
Yu, Dongke
Song, Zhiheng
Niu, Lihong
Zhang, Lijuan
Shi, Jianyou
Advances in RIPK1 kinase inhibitors
title Advances in RIPK1 kinase inhibitors
title_full Advances in RIPK1 kinase inhibitors
title_fullStr Advances in RIPK1 kinase inhibitors
title_full_unstemmed Advances in RIPK1 kinase inhibitors
title_short Advances in RIPK1 kinase inhibitors
title_sort advances in ripk1 kinase inhibitors
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554302/
https://www.ncbi.nlm.nih.gov/pubmed/36249746
http://dx.doi.org/10.3389/fphar.2022.976435
work_keys_str_mv AT chenlu advancesinripk1kinaseinhibitors
AT zhangxiaoqin advancesinripk1kinaseinhibitors
AT ouyaqing advancesinripk1kinaseinhibitors
AT liumaoyu advancesinripk1kinaseinhibitors
AT yudongke advancesinripk1kinaseinhibitors
AT songzhiheng advancesinripk1kinaseinhibitors
AT niulihong advancesinripk1kinaseinhibitors
AT zhanglijuan advancesinripk1kinaseinhibitors
AT shijianyou advancesinripk1kinaseinhibitors